Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in brain excitatory neurons (12 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 134 | 0.82 |
| pathways Reactome | 38 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 7740
Sealed predictions
- FGF17 in dopamine neurons, braak-0.47 (p 0.197) → -0.63 (p 0.068)receipt 7747
Swarm cases
receipt 7747: FGF17 in dopamine neurons, braak
- power
- full sample -0.56 (p 0.017, n 18), 95% CI -0.81 to -0.12. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.58 (p 0.012, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.69 (p 0.0016, n 18). not the mix.
- skeptic
- leave-one-out range -0.69 to -0.50, sign flips 0; without severely affected donors -0.56 (p 0.017, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FGF17 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts